Cohen-Cohen Salomon, Scheitler Kristen M, Choby Garret, Janus Jeffrey, Moore Eric J, Kasperbauer Jan L, Cloft Harry J, Link Michael, Gompel Jamie J Van
Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, United States.
Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota, United States.
J Neurol Surg B Skull Base. 2021 Mar 2;83(Suppl 2):e266-e273. doi: 10.1055/s-0041-1725031. eCollection 2022 Jun.
Juvenile nasopharyngeal angiofibromas (JNAs) are uncommon tumors with an evolving treatment paradigm. The objective of this study was to compare our prior experience reported in 2005 with our most contemporary series to compare practice improvements and the impact of expanded endonasal procedures. Retrospective review comparing a contemporary 22 patients with JNA who underwent surgical management between 2005 and 2019, compared with a historical cohort of 65 patients from the same center. The most common presenting symptom was epistaxis (68%). The median maximum tumor diameter was 4.4 cm. All patients underwent preoperative embolization. An endoscopic endonasal approach (EEA) was used in 18 patients (82%), compared with 9% in the series prior to 2005. Gross total resection was achieved in all patients. The median estimated blood loss was 175 and 350 mL for EEA and open (transfacial) cases, respectively. Only two patients (9%) required a blood transfusion compared with 52% on the previous series. The median follow-up was 19 months. The overall recurrence rate was 9% in this series and 24% in the previous series. No patient required radiation therapy in follow-up compared with 3% in our historical cohort. There have been significant changes regarding the management of patients with JNA compared with the previous Mayo Clinic experience. The EEA has become the preferred route over the transfacial approaches to treat JNA in selected patients who do not have intracranial extension. Preoperative embolization has aided in reducing the postoperative transfusion rates.
青少年鼻咽血管纤维瘤(JNAs)是一种少见的肿瘤,其治疗模式不断演变。本研究的目的是将我们2005年报告的既往经验与最新系列病例进行比较,以对比实践中的改进以及扩大鼻内镜手术的影响。
回顾性比较2005年至2019年间接受手术治疗的22例当代JNA患者,与同一中心65例历史队列患者。
最常见的首发症状是鼻出血(68%)。肿瘤最大直径的中位数为4.4厘米。所有患者均接受了术前栓塞。18例患者(82%)采用了鼻内镜鼻内入路(EEA),而2005年之前的系列病例中这一比例为9%。所有患者均实现了肿瘤全切。EEA和开放(经面部)手术病例的估计失血量中位数分别为175毫升和350毫升。本系列中只有2例患者(9%)需要输血,而之前的系列为52%。中位随访时间为19个月。本系列的总体复发率为9%,之前的系列为24%。随访中没有患者需要放疗,而我们的历史队列中这一比例为3%。
与梅奥诊所之前的经验相比,JNA患者的治疗管理发生了显著变化。对于没有颅内扩展的特定患者,EEA已成为治疗JNA优于经面部入路的首选途径。术前栓塞有助于降低术后输血率。